India, March 24 -- Opthea Limited (OPT), a clinical-stage biopharmaceutical company focused on retinal diseases, including wet age-related macular degeneration or wet AMD, announced Monday that its global Phase 3 clinical trial COAST (Combination OPT-302 with Aflibercept Study) in patients with wet AMD failed to meet primary endpoint.
The company said it is considering impact of negative trial results under its Development Funding Agreement or DFA and on the company as a going concern.
The COAST Phase 3 trial evaluated the efficacy and safety of intravitreally administered 2 mg sozinibercept every four or eight weeks in combination with 2 mg aflibercept, as per label, every eight weeks after a loading phase for the treatment of wet AMD. T...